Protection against experimental melioidosis following immunisation with a lipopolysaccharide-protein conjugate

Area of Science:

• Immunology
• Microbiology
• Vaccinology

Background:

• Melioidosis is a severe infectious disease caused by Burkholderia pseudomallei.
• The disease is difficult to treat with antibiotics and lacks a licensed vaccine.
• Burkholderia pseudomallei poses a significant global health challenge.

Purpose of the Study:

• To develop and evaluate a novel conjugate vaccine against melioidosis.
• To assess the protective efficacy of a B. pseudomallei lipopolysaccharide-tetanus toxin conjugate in a mouse model.
• To investigate the immune response elicited by the conjugate vaccine.

Main Methods:

• Construction of a polysaccharide-protein conjugate using B. pseudomallei lipopolysaccharide and tetanus toxin Hc fragment.
• Immunization of mice with the conjugate vaccine.
• Assessment of bacterial burden in spleen post-challenge with B. pseudomallei.
• Analysis of antigen-specific IgG1 and IgG2a antibody levels and T-helper cell responses.

Main Results:

• Mice immunized with the conjugate showed significantly reduced bacterial loads in the spleen.
• The conjugate vaccine provided significant protection against lethal B. pseudomallei challenge.
• Conjugate immunization induced higher levels of antigen-specific IgG1 and IgG2a compared to unconjugated lipopolysaccharide.
• The conjugate vaccine promoted a Th1-biased immune response, indicated by high IgG2a levels.

Conclusions:

• The developed lipopolysaccharide-conjugate vaccine is effective in protecting against melioidosis in mice.
• This conjugate vaccine strategy holds promise for the development of a viable vaccine against melioidosis.
• The study highlights the potential of conjugate vaccines in eliciting protective immunity against challenging bacterial infections.